A Phase 1, Open-label, Dose-escalation, Safety and Biomarker Prediction of Alvocidib and Cytarabine/Daunorubicin (7+3) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
Study of Drug in Patients with Acute Myeloid Leukemia (AML)
Sponsor: Tolero Pharmaceuticals
Enrolling: Male and Female Patients
IRB Number: AAAR4394
U.S. Govt. ID: NCT03298984
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to measure the effectiveness and safety of an investigational drug called "alovicidib" in combination with cytarabine and daunorubicin in the treatment of AML. Investigational means that this drug has not been approved by the FDA. Cytarabine and daunorubicin are both standard of care treatments for patients with AML. Subjects participating in this clinical trail may remain on study for 3-9 months, depending on how they respond to treatment.
This study is closed
Investigator
Daniel Lee, MD
Do You Qualify?
Are you between 18 and 65 years of age? Yes No
Have you been diagnosed with acute myeloid leukemia (AML)? Yes No
Are you able to walk, care for yourself, and do light physical activities like light housework or office work? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE